Sepsis – Global Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Sepsis
– Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s
offering.

Sepsis – Pipeline Review, H1 2019 provides
comprehensive information on the therapeutics under development for
Sepsis (Infectious Disease), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.

The Sepsis (Infectious Disease) pipeline guide also reviews of key
players involved in therapeutic development for Sepsis and features
dormant and discontinued projects. The guide covers therapeutics under
Development by Companies/Universities/Institutes, the molecules
developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed,
Preclinical, Discovery and Unknown stages are 5, 9, 7, 1, 53, 6 and 3
respectively. Similarly, the Universities portfolio in Preclinical and
Discovery stages comprises 23 and 2 molecules, respectively.

Scope

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Sepsis (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Sepsis
  (Infectious Disease) by companies and universities/research institutes
  based on information derived from company and industry-specific
  sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise, product description, descriptive licensing
  and collaboration details, R&D brief, MoA & other developmental
  activities.
• The pipeline guide reviews key companies involved in Sepsis
  (Infectious Disease) therapeutics and enlists all their major and
  minor projects.
• The pipeline guide evaluates Sepsis (Infectious Disease) therapeutics
  based on mechanism of action (MoA), drug target, route of
  administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Sepsis (Infectious Disease).

Reasons to Buy

• Procure strategically important competitor information, analysis, and
  insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio
  and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under
  development for Sepsis (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of
  leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players
  and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding
  Sepsis (Infectious Disease) pipeline depth and focus of Indication
  therapeutics.
• Develop and design in-licensing and out-licensing strategies by
  identifying prospective partners with the most attractive projects to
  enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects
  and understand from the know-how what drove them from pipeline.

Key Topics Covered

1. Introduction
2. Sepsis – Overview
3. Therapeutics Development
4. Therapeutics Assessment
5. Companies Involved in Therapeutics Development
6. Drug Profiles
7. Dormant Projects
8. Discontinued Products
9. Product Development Milestones
10. Appendix

Companies Mentioned

• Adrenomed AG
• Am-Pharma BV
• Arch Biopartners Inc
• Asahi Kasei Pharma Corp
• Atox Bio Ltd
• Aurigene Discovery Technologies Ltd
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Co
• Cell2B Advanced Therapeutics SA
• Cells for Cells SA
• China Grand Pharmaceutical & Healthcare Holdings Ltd
• Chongqing Zhifei Biological Products Co Ltd
• Cilian AG
• Cynata Therapeutics Ltd
• CytaCoat AB
• Dr. Franz Kohler Chemie GmbH
• Endacea Inc
• Enlivex Therapeutics Ltd
• Enzychem Lifesciences Corp
• Evec Inc
• Immunwork Inc
• InflaRx NV
• Integrated BioTherapeutics Inc
• Lead Discovery Center GmbH
• MetrioPharm AG
• Microbiotix Inc
• Mochida Pharmaceutical Co Ltd
• Nosopharm SAS
• OncoImmune Inc
• Ono Pharmaceutical Co Ltd
• Opsona Therapeutics Ltd
• ProThera Biologics Inc
• Q BioMed Inc
• Ra Pharmaceuticals Inc
• Recce Ltd
• Regeneron Pharmaceuticals Inc
• Ribomic Inc
• Rimonyx Pharmaceuticals Ltd
• SciClone Pharmaceuticals Inc
• SetLance srl
• Shionogi & Co Ltd
• SK Biopharmaceuticals Co Ltd
• Syntiron LLC
• Takeda Pharmaceutical Co Ltd
• Therakind Ltd
• Therashock LLC
• Vascular BioSciences

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/9btouc

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Infectious
Diseases Drugs